疏血通注射液与舒血宁注射液治疗急性缺血性脑卒中疗效的队列研究

Cohort Study on Therapeutic Efficacy of SXT and SXN Injection in the Treatment of Acute Ischemic Stroke

目的:为临床合理利用疏血通注射液(SXT)与舒血宁注射液(SXN)治疗急性缺血性脑卒中(AIS)提供参考。方法:调查北京某"三甲"医院2008-2009年使用SXT或SXN治疗AIS住院患者的信息,对患者的一般情况,用药前后患者的生命体征、美国国家健康协会国家神经障碍及脑卒中学会脑卒中评分量表(NIH-NIDS)评分进行比较。结果:SXT与SXN治疗AIS患者的总疗效比较差异无统计学意义(P>0.05);在治疗椎基底动脉AIS患者时,SXN疗效优于SXT(P<0.05);在治疗高血糖的AIS患者时,SXT疗效优于SXN(P<0.05);在治疗伴随高同型半胱氨酸血症的AIS患者时,SXN疗效明显优于SXT(P<0.05)。结论:在AIS治疗中,应根据患者梗塞部位,血糖及血同型半胱氨酸等情况选择使用SXN或SXT。

OBJECTIVE：To provide reference for rational use of SXT injection and SXN injection in the treatment of acute ischemic stroke（AIS）.METHODS：AIS inpatients treated with SXT and SXN injection in a third-grade class-A hospital during 2008-2009 were investigated.The general information,vital signs,and NIH-NIDS score of the cases were compared before and after treatment.RESULTS：There was no statistical difference in therapeutic efficacy of SXT and SXN injection in the treatment of AIS（P0.05）.For treatment of vertebrobasilar artery occlusion,the effect of SXN injection was significantly better than the SXT injection（P0.05）;for treatment of AIS patients with hyperglycemia,the effect of SXT injection was better than SXN injection（P0.05）;for treatment of AIS patients with hyperhomocysteinemia（HCY）,the efficacy of SXN injection was better than SXT injection（P0.05）.CONCLUSION：The site of infarction,blood sugar,and blood HCY should be considered when selecting SXT or SXN injection for AIS patients.